Literature DB >> 21768612

Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study.

Oliver D Howes1, Subrata K Bose, Federico Turkheimer, Isabel Valli, Alice Egerton, Lucia R Valmaggia, Robin M Murray, Philip McGuire.   

Abstract

OBJECTIVE: While there is robust evidence of elevated dopamine synthesis capacity once a psychotic disorder has developed, little is known about whether it is altered prior to the first episode of frank illness. The authors addressed this issue by measuring dopamine synthesis capacity in individuals at ultra-high risk of psychosis and then following them to determine their clinical outcome.
METHOD: This prospective study included 30 patients who met standard criteria for being at ultra-high risk of psychosis and 29 healthy volunteers. Participants were scanned using [(18)F]6-fluoro-L-dopa positron emission tomography. The ultra-high-risk patients were scanned at presentation and followed up for at least 3 years to determine their clinical outcome. Six patients had comorbid schizotypal personality disorder and were excluded from the analysis (data are provided for comparison). Of the remaining patients, nine developed a psychotic disorder (psychotic transition group) and 15 did not (nontransition group).
RESULTS: There was a significant effect of group on striatal dopamine synthesis capacity. The psychotic transition group had greater dopamine synthesis capacity in the striatum (effect size=1.18) and its associative subdivision (effect size=1.24) than did the healthy comparison subjects and showed a positive correlation between dopamine synthesis capacity and symptom severity. Dopamine synthesis capacity was also significantly greater in the psychotic transition group than in the nontransition group.
CONCLUSIONS: These findings provide evidence that the onset of frank psychosis is preceded by presynaptic dopaminergic dysfunction. Further research is needed to determine the specificity of elevated dopamine synthesis capacity to particular psychotic disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21768612      PMCID: PMC3682447          DOI: 10.1176/appi.ajp.2011.11010160

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  39 in total

Review 1.  Dopaminergic dysfunction in schizophrenia: salience attribution revisited.

Authors:  Andreas Heinz; Florian Schlagenhauf
Journal:  Schizophr Bull       Date:  2010-05-07       Impact factor: 9.306

2.  Multi-resolution Bayesian regression in PET dynamic studies using wavelets.

Authors:  F E Turkheimer; J A D Aston; M-C Asselin; R Hinz
Journal:  Neuroimage       Date:  2006-04-27       Impact factor: 6.556

3.  Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum.

Authors:  Diana Martinez; Mark Slifstein; Allegra Broft; Osama Mawlawi; Dah-Ren Hwang; Yiyun Huang; Thomas Cooper; Lawrence Kegeles; Eric Zarahn; Anissa Abi-Dargham; Suzanne N Haber; Marc Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2003-03       Impact factor: 6.200

4.  Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats.

Authors:  C J Pycock; R W Kerwin; C J Carter
Journal:  Nature       Date:  1980-07-03       Impact factor: 49.962

5.  Increased synaptic dopamine function in associative regions of the striatum in schizophrenia.

Authors:  Lawrence S Kegeles; Anissa Abi-Dargham; W Gordon Frankle; Roberto Gil; Thomas B Cooper; Mark Slifstein; Dah-Ren Hwang; Yiyun Huang; Suzanne N Haber; Marc Laruelle
Journal:  Arch Gen Psychiatry       Date:  2010-03

6.  Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study.

Authors:  J S Rakshi; T Uema; K Ito; D L Bailey; P K Morrish; J Ashburner; A Dagher; I H Jenkins; K J Friston; D J Brooks
Journal:  Brain       Date:  1999-09       Impact factor: 13.501

Review 7.  Do we still believe in the dopamine hypothesis? New data bring new evidence.

Authors:  Anissa Abi-Dargham
Journal:  Int J Neuropsychopharmacol       Date:  2004-03       Impact factor: 5.176

8.  Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals.

Authors:  Daqiang Sun; Lisa Phillips; Dennis Velakoulis; Alison Yung; Patrick D McGorry; Stephen J Wood; Theo G M van Erp; Paul M Thompson; Arthur W Toga; Tyrone D Cannon; Christos Pantelis
Journal:  Schizophr Res       Date:  2009-01-12       Impact factor: 4.939

Review 9.  The dopamine hypothesis of schizophrenia: version III--the final common pathway.

Authors:  Oliver D Howes; Shitij Kapur
Journal:  Schizophr Bull       Date:  2009-03-26       Impact factor: 9.306

10.  Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe.

Authors:  Alexander Hammers; Richard Allom; Matthias J Koepp; Samantha L Free; Ralph Myers; Louis Lemieux; Tejal N Mitchell; David J Brooks; John S Duncan
Journal:  Hum Brain Mapp       Date:  2003-08       Impact factor: 5.038

View more
  140 in total

Review 1.  Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments.

Authors:  George Bartzokis
Journal:  Neuropharmacology       Date:  2012-01-28       Impact factor: 5.250

2.  [Should antipsychotics be used in prodromal stages of schizophrenia to prevent psychosis? Pro].

Authors:  M Lambert; C Correll
Journal:  Nervenarzt       Date:  2015-11       Impact factor: 1.214

3.  Dopaminergic function in the psychosis spectrum: an [18F]-DOPA imaging study in healthy individuals with auditory hallucinations.

Authors:  Oliver D Howes; Paul Shotbolt; Michael Bloomfield; Kirstin Daalman; Arsime Demjaha; Kelly M J Diederen; Kemal Ibrahim; Euitae Kim; Philip McGuire; René S Kahn; Iris E Sommer
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

4.  Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies.

Authors:  Paolo Fusar-Poli; Andreas Meyer-Lindenberg
Journal:  Schizophr Bull       Date:  2012-01-26       Impact factor: 9.306

5.  Abnormalities in hemispheric specialization of caudate nucleus connectivity in schizophrenia.

Authors:  Sophia Mueller; Danhong Wang; Ruiqi Pan; Daphne J Holt; Hesheng Liu
Journal:  JAMA Psychiatry       Date:  2015-06       Impact factor: 21.596

Review 6.  Attenuated psychosis syndrome in DSM-5.

Authors:  Ming T Tsuang; Jim Van Os; Rajiv Tandon; Deanna M Barch; Juan Bustillo; Wolfgang Gaebel; Raquel E Gur; Stephan Heckers; Dolores Malaspina; Michael J Owen; Susan Schultz; William Carpenter
Journal:  Schizophr Res       Date:  2013-06-14       Impact factor: 4.939

7.  Childhood onset schizophrenia and early onset schizophrenia spectrum disorders.

Authors:  David I Driver; Nitin Gogtay; Judith L Rapoport
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2013-06-18

Review 8.  Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies.

Authors:  Christin Schifani; Sina Hafizi; Tania Da Silva; Jeremy Joseph Watts; M Saad Khan; Romina Mizrahi
Journal:  Int Rev Psychiatry       Date:  2017-12-08

9.  Uncovering the role of the nucleus accumbens in schizophrenia: A postmortem analysis of tyrosine hydroxylase and vesicular glutamate transporters.

Authors:  Lesley A McCollum; Rosalinda C Roberts
Journal:  Schizophr Res       Date:  2015-09-18       Impact factor: 4.939

10.  An augmented dopamine system function is present prior to puberty in the methylazoxymethanol acetate rodent model of schizophrenia.

Authors:  Li Chen; Stephanie M Perez; Daniel J Lodge
Journal:  Dev Neurobiol       Date:  2014-03-03       Impact factor: 3.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.